Search results
Showing 226 to 240 of 1094 results for infections
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Recommendation ID NG25/2 Question Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the...
This quality standard covers blood transfusion and reducing the requirements for blood transfusion in adults, young people and children aged 1 year and over. It describes high-quality care in priority areas for improvement. It does not cover use of tranexamic acid for surgery during pregnancy or labour or blood transfusion during pregnancy or labour.
View quality statements for QS138Show all sections
Sections for QS138
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (HTG300)
Evidence-based recommendations on deep dermal injection of non absorbable gel polymer for HIV-related facial lipoatrophy. This involves injecting the gel polymer under the skin to restore the shape and volume of the areas where fat has been lost.
View recommendations for HTG300Show all sections
Sections for HTG300
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for HTG717Show all sections
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
could be used to encourage people at increased risk of hepatitis B and C infection to take up the offer of testing and treatment? Any...
This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .